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Abstract
Background: To date, 43 types of Spinocerebellar Ataxias (SCAs) have been identified. A subset of the SCAs are
caused by the pathogenic expansion of a CAG repeat tract within the corresponding gene. Ethnic and geographic
differences are evident in the prevalence of the autosomal dominant SCAs. Few descriptions of the clinical
phenotype and molecular genetics of the SCAs are available from the African continent. Established studies
mostly concern the South African populations, where there is a high frequency of SCA1, SCA2 and SCA7. The
SCA7 mutation in South Africa (SA) has been found almost exclusively in families of indigenous Black African
ethnic origin.
Objective: To present the results of the first clinical description of seven Zambian families presenting with
autosomal dominant SCA, as well as the downstream molecular genetic analysis of a subset of these families.
Methods: The study was undertaken at the University Teaching Hospital in Lusaka, Zambia. Ataxia was quantified with
the Brief Ataxia Rating Scale derived from the modified international ataxia rating scale. Molecular genetic testing for 5
types of SCA (SCA1, SCA2, SCA3, SCA6 and SCA7) was performed at the National Health Laboratory Service at Groote
Schuur Hospital and the Division of Human Genetics, University of Cape Town, SA. The clinical and radiological features
were evaluated in seven families with autosomal dominant cerebellar ataxia. Molecular genetic analysis was completed
on individuals representing three of the seven families.
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Results: All affected families were ethnic Zambians from various tribes, originating from three different regions of the
country (Eastern, Western and Central province). Thirty-four individuals from four families had phenotypic features of
SCA7. SCA7 was confirmed by molecular testing in 10 individuals from 3 of these families. The age of onset of the
disease varied from 12 to 59 years. The most prominent phenotypic features in these families were gait and limb
ataxia, dysarthria, visual loss, ptosis, ophthalmoparesis/ophthalmoplegia, pyramidal tract signs, and dementia. Affected
members of the SCA7 families had progressive macular degeneration and cerebellar atrophy. All families displayed
marked anticipation of age at onset and rate of symptom progression. The pathogenic SCA7 CAG repeat ranges varied
from 47 to 56 repeats. Three additional families were found to have clinical phenotypes associated with autosomal
dominant SCA, however, DNA was not available for molecular confirmation. The age of onset of the disease in these
families varied from 19 to 53 years. The most common clinical picture in these families included a combination of
cerebellar symptoms with slow saccadic eye movements, peripheral neuropathy, dementia and tremor.
Conclusion: SCA is prevalent in ethnic Zambian families. The SCA7 families in this report had similar clinical
presentations to families described in other African countries. In all families, the disease had an autosomal dominant
pattern of inheritance across multiple generations. All families displayed anticipation of both age of onset and the rate
of disease progression. Further clinical and molecular investigations of the inherited ataxias in a larger cohort
of patients is important to understand the natural history and origin of SCAs in the Zambian population.
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Background
African populations are characterized by high levels of
genetic and geographic diversity, and extensive population
substructure [1]. Studies of the genetic basis of neuro-
logical diseases in African populations can improve our
understanding of novel mechanisms of disease pathogen-
esis and the origins of pathogenic mutations. However,
there is very little data on the clinical spectrum, frequency
and genetics of hereditary neurological diseases from the
African continent. The autosomal dominant cerebellar
ataxias (ADCAs), also known as the inherited spinocere-
bellar ataxias (SCAs), are a clinically and genetically
heterogeneous group of progressive neurodegenerative
disorders, characterized primarily by degeneration of the
cerebellum, brainstem, and spinal cord. Clinically, the
cerebellar syndrome (gait and limb ataxia, dysarthria, and
nystagmus) is often associated with non-ataxia symptoms,
such as pyramidal signs, ophthalmoplegia, visual disor-
ders, seizures and peripheral neuropathy [2–4]. Pheno-
types of different SCAs often overlap; therefore, clinical
diagnosis remains a challenge.
More than 40 genes have been found to be associated
with the SCAs, with SCA44 recently identified [5]. The most
common types of SCAs worldwide include SCA1, SCA2,
SCA3, SCA6, SCA7, and dentatorubral-pallidoluysian atro-
phy (DRPLA), all caused by unstable trinucleotide repeat
Cytosine-Adenine-Guanine (CAG) expansions in the coding
region of the respective genes [3, 6]. The size of the CAG
repeat and the age at onset are inversely correlated: the
longer the repeat, the earlier the age at onset.
Few studies on the clinical spectrum, frequency, and
genetics of the SCAs are available from the African con-
tinent [7, 8]. Established studies mostly concern the South
African populations, where there is a high frequency of
SCA1, SCA2 and SCA7 [9–12]. Moreover, the SCA7 mu-
tation in South Africa (SA) has been found almost exclu-
sively in families of Black ethnic origin [10–13]. There is
no published data on the spectrum of the SCAs in the
Zambian population.
The objective of this study was to describe the clinical
phenotype in seven Zambian families with autosomal
dominant SCA, and perform molecular analyses on a sub-
set of these families in order to confirm clinical findings.
Methods
Patients and families
The study was conducted at the University Teaching Hos-
pital (UTH) in Lusaka, Zambia. UTH is the major teaching
hospital for the University of Zambia School of Medicine
(UNZA-SOM) and the main tertiary care center in Zambia.
The Republic of Zambia is a landlocked country in the cen-
tral part of southern Africa with a population of more than
15 million people. Although more than 70 different tribes
are currently recognized, the Zambian population can be
classified within the Niger-Kordofanian family, the largest
of the four ethno-linguistic African macrofamilies [14]. Five
ethnic Zambian families and two mixed (Zambian/Sierra-
Leonean and Zambian/Zimbabwean) families with sus-
pected SCA were examined between 2008 and 2015. Fig. 1
shows the pedigree of each family.
A neurologist (MA) examined probands, affected,
and unaffected family members. The inclusion cri-
teria included progressive cerebellar ataxia with or
without associated extracerebellar symptoms, and a
positive familial history compatible with autosomal
dominant inheritance. Patients with ataxia possibly
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associated with abuse of alcohol or other substances
and diseases, including HIV infection, were excluded.
Ataxia was quantified with the Brief Ataxia Rating
Scale (BARS) with a total rating score of 30, which
is derived from the modified international ataxia rat-
ing scale [15]. Dementia was quantified with MMSE
(Mini-mental state examination). The probands
underwent routine laboratory testing and brain CT
and/or MRI. Molecular genetic testing for SCA types
was performed on 3 families at the National Health
Laboratory Service (NHLS) at Groote Schuur Hos-
pital and the Division of Human Genetics, University
of Cape Town (UCT), South Africa (SA). All pro-
bands and family members who provided DNA sam-
ples gave written informed consent, and the study
was approved by the Biomedical Research Ethics
Committee of the University of Zambia. At the
University of Cape Town (UCT), ethical approval
Fig. 1 Family pedigrees of patients with spinocerebellar ataxia
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was granted by the institutional Human Research
Ethics Committee (HREC REF 229/2010 and 217/
2010, renewed annually).
Genetic analysis
Genomic DNA was isolated from peripheral blood sam-
ples in the Department of Internal Medicine UNZA/
UTH in Lusaka using standard protocols and shipped to
the Division of Human Genetics, UCT. The National
Health Laboratory Service (NHLS) at Groote Schuur
Hospital in Cape Town is the only centre in southern
Africa that offers molecular genetic testing for the poly-
glutamine SCAs (SCA1, SCA2, SCA3, SCA6, SCA7 and
SCA17) since testing was initiated in 1987 [11]. The
CAG repeat region within each causative gene for this
study was amplified using a multiplex PCR method [16]
or a triplet-primed PCR (TP PCR) assay [17], followed
by capillary electrophoresis on the ABI 3100 Genetic
Analyzer (Applied Biosystems). The sizes of the repeats
were determined by comparison with the GeneScan 500
Rox Size Standard (Applied Biosystems). Where TP PCR
was used, the CAG repeat genotype of the individual
was denoted using N to indicate an allele within the
unaffected range, and E to indicate a pathogenically ex-
panded allele (Table 1). Each run included positive con-
trol samples of known CAG repeat length.
Results
Seven families with autosomal dominant cerebellar
ataxia were identified. Three families had molecularly
confirmed SCA7. Another family had a clinical pheno-
type suggestive of SCA7 but did not undergo genetic
testing. Three additional families were found to have
clinical phenotypes associated with autosomal dominant
SCA, but genetic material was not available for molecu-
lar confirmation.
Accessible family members in different generations
who were available for examination manifested with
similar clinical phenotypes.
Clinical and radiological data of 19 patients with auto-
somal dominant spinocerebellar ataxia are presented
in Table 1. The mean age at onset (32 ± 14, range 12-73)
was not significantly different in males and females. All
patients had progressive cerebellar ataxia. In 15 of the
19 patients ataxia was associated with decreased visual
acuity, ptosis and ophthalmoplegia. Pigmentary macular
degeneration was found in 8 of them, optic atrophy in 3
and both symptoms were evident in 4. Nine patients had
symptoms of dementia. Six patients had tremor, dystonia
and other extrapyramidal symptoms. Almost all patients
had increased reflexes, but in 4 individuals it was associ-
ated with spasticity of the lower limbs and peripheral
sensory neuropathy. Various degrees of cerebellar or
olivo-ponto-cerebellar atrophy on CT or MRI was found
in all 19 patients with additional cortical atrophy in ten.
The pathogenic SCA7 CAG repeat ranges varied from
47 to 56 repeats.
Family 1
Family 1 was from the Bemba tribe in the Copperbelt
(Kitwe) region. The proband (iii.11) was 14 years old
at examination, and presented with progressive cere-
bellar symptoms and visual loss starting at 12 years.
The general physical examination was normal. The
neurological examination revealed severe gait ataxia,
limbs ataxia, bilateral ptosis, bilateral pyramidal symp-
toms and external ophthalmoparesis. Sensation was
normal. MMSE showed a mild mental impairment.
Fundoscopy revealed bilateral macular degeneration.
A CT scan of the brain revealed cerebellar atrophy,
confirmed by MRI. The proband died at age 21 from
pneumonia. The father of the proband didn’t have
any neurological symptoms. The brother (iii.12) of the
proband was asymptomatic up to 17 years old, but
had developed visual problems several months before
examination. The general physical examination was
normal, but neurological examination revealed mild
bilateral ptosis and depressed reflexes. Fundoscopy re-
vealed bilateral macular degeneration (Fig. 2a).
The mother (ii.16) of the proband was one of 13 chil-
dren. Five of her siblings had similar clinical features of
progressive ataxia, visual loss, dysarthria and spasticity.
Her symptoms started at age 29. She presented with pro-
gressive gait ataxia, blindness, bilateral ptosis and
ophthalmoparesis, dysarthria, bulbar symptoms, dystonic
movements of the limbs, spasticity and dementia. Fun-
doscopy revealed retinopathy along with optic atrophy.
CT and MRI showed mild cerebral and severe cerebellar
atrophy. She lost vision at age 32, and died at age 36.
Molecular genetic analysis of the proband, his brother,
and three maternal family members revealed ataxin-7
repeats within the disease-causing range (Table 1). MRI
brain of the affected aunts (ii.10, ii.13) and uncles (ii.11,
ii.19) showed various degrees of olivo-ponto-cerebellar
atrophy with cortical atrophy which progressed during
6 years of observation. Cortical atrophy was correlated
with cognitive impairment. All of them had decreased
visual acuity associated with varying degrees of macular
pigmentary changes on ophthalmoscopy. Clinical fea-
tures of the extended family are presented in Table 1.
Family 2
Family 2 was from the town of Mongu in western
Zambia (Lozi tribe). The proband (iii.1) was a 33-year-
old male who presented with progressive ataxia and poor
vision over a period of 4 years. The neurological examin-
ation revealed severe gait ataxia, symmetrical ataxia of
limbs, dysmetria, dysarthria, slowing of eye movements,
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bilateral pyramidal symptoms, peripheral sensory neur-
opathy, dementia and euphoria. Ophthalmic examination
revealed decreased visual acuity in 85% and bilateral pig-
mentary macular degeneration along with optic atrophy.
MRI scan of the brain showed severe diffuse cerebral and
pontocerebellar atrophy. Cortical atrophy was correlated
with significant cognitive decline. He had 2 daughters, both
in good health. The brother (iii.3) of the proband was
30 years old. All neurological, ophthalmologic and imaging
findings were similar to the proband. The mother (ii.2) of
the proband and her 3 sisters had severe balance and vision
problems, which started in their mid-50s and 60s. These
relatives were not examined. Molecular genetic testing con-
firmed the diagnosis of SCA7 in the proband and his
brother.
Family 3
Family 3 was from the city of Chipata in eastern Zambia.
The proband (iv.10) was a 26-year old female who pre-
sented with progressive reduction in visual acuity and dif-
ficulty with walking due to severe imbalance, which
started 4 years prior to examination. She had severe bilat-
eral and symmetrical ataxia of lower limbs and gait, but
mild ataxia in the arms. She had mild bilateral ptosis
without ophthalmoparesis, and slowing of eye movements.
Very mild fasciculation of the tongue and bilateral
pyramidal signs (very high tendon reflexes, bilateral
clonus and Babinski sign), as well as mild distal
hypoesthesia of lower limbs. Fundoscopy revealed
bilateral macular degeneration and optic atrophy
(Fig. 2c). MRI of the brain showed mild cerebral and
cerebellar atrophy (Fig. 2d). The proband had 2
healthy children. The mother of the proband (iii.11),
from the Ngoni tribe, did not have any neurological
symptoms. Her other four children did not have any
history of imbalance or poor vision. The mother’s
brothers, sisters and their children were healthy.
The father (iii.10) of the proband, from the Kunda
tribe, was affected with the same condition. At age 56
he started progressive reduction in visual acuity (over
4 years) and difficulty in walking due to severe imbal-
ance. Of his four sisters, 3 (iii.7, iii.8 and iii.9) had
similar symptoms such as reduced visual acuity, se-
vere gait ataxia, and loss of memory. These symptoms
started at age 49, 50 and 52. Clinical features of ex-
tended family members are presented in Table 1. No
genetic material was available for molecular confirm-
ation of diagnosis.
Fig. 2 a Photograph of the right fundus of the proband’s brother of Family 1 (iii.12), showing macular degeneration. b T2-weighted MRI brain of
patient ii.10 of Family 1 demonstrating diffuse cerebral and cerebellar atrophy, and mild brainstem atrophy. c Photograph of the right fundus of
individual iv.10 of Family 3 showing macular degeneration and optic atrophy. d T2-weighted MRI brain of individual iv.10 of Family 3 showing
mild cerebral and cerebellar atrophy
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Family 4
Family 4 was from the Nyanja tribe. The proband (iv.12)
was a 25-year old female who reported onset of gait dif-
ficulties at age 16, which was later associated with pro-
gressive loss of vision. She also complained of dysphagia.
The general physical examination was normal. Her
neurological examination revealed severe gait ataxia,
limbs ataxia, dysarthria, bilateral ptosis and external
ophthalmoparesis, along with bulbar and bilateral pyr-
amidal symptoms. Sensation was normal. Her mental
examination showed a moderate mental impairment.
Fundoscopy revealed bilateral macular degeneration and
optic atrophy. A CT and MRI scan of the brain revealed
cerebellar and diffuse cerebral atrophy. Her father (iii.8)
was examined at the age 68. His balance and visual
problems started at age 60. He was unable to walk with-
out assistance and nearly blind. Neurological examin-
ation was positive for cerebellar ataxia, macular
retinopathy, ophthalmoparesis, slurred speech, bulbar
and bilateral pyramidal symptoms. He had severe de-
mentia. MRI of the brain revealed diffuse cerebral and
cerebellar atrophy. His father (ii.5) (grandfather of the
proband), who was Zimbabwean had developed gait
ataxia, poor vision and blurring speech at the age of
70. Two cousins of the proband’s father had similar
symptoms which started at ages 32 and 35. The pro-
band’s cousin (iv.2) developed gait disturbances and
poor vision at the age 19 and died at the age of 28.
A diagnosis of SCA7 was molecularly confirmed in
the proband and his father (Table 1).
Family 5
Family 5 was from the Ngoni tribe. The proband (iii.4) was
a 36-year old female, presenting with an 8-year history of
gradual progression in difficulty walking and slurred speech.
Neurological examination demonstrated gait and limbs
ataxia, dysarthria, slow ocular saccades, mild ophthal-
moparesis, bilateral distal sensory neuropathy, hands
tremor and mild dementia. Fundoscopy did not show
retinopathy or maculopathy. CT of the brain showed
mild cerebral and moderate cerebellar atrophy. Her
three children and siblings were asymptomatic.
The mother (ii.2) of the proband had limb ataxia from
age 53, and had developed peripheral motor and sensory
neuropathy by the age of 58. Her fundoscopy was unre-
markable, CT of the brain showed cerebellar atrophy. Her
four brothers were affected with similar symptoms, with
unsteadiness starting after age 40. Affected siblings of the
mother had not been examined. No genetic material was
available for molecular confirmation of diagnosis.
Family 6
Family 6 was from Livingstone in southwestern Zambia
(Lozi tribe). The proband (iii.7) was a 25-year old female
who presented with a 6-year history of progressive un-
steadiness and hand shaking. The general physical exam-
ination was normal. Neurological examination revealed
severe limb, truncal, and gait ataxia. There was also dys-
arthria, and a persistent head and hand resting tremor.
She had mild dementia, slow saccadic eye movements
and reduced deep tendon reflexes. Sensation was intact.
Fundoscopy was unremarkable. MRI of the brain showed
cerebellar atrophy and mild pons atrophy. Her two sisters
(iii.2, iii.6) had developed limb and gait ataxia and resting
tremor of hands since ages 23 and 26. The proband’s
mother (ii.2) did not report any neurological symptoms and
was clinically healthy. The proband’s father (ii.1), paternal
grandmother (i.2), uncles (ii.3, ii.7. ii.10) and aunts (ii.4, ii.5)
had similar symptoms. Ataxia, dystonia, tremor of hands,
saccadic eye movements and symptoms of peripheral
neuropathy were the main symptoms of affected members
of the family, which started at age 68 (ii.1), 73 (i.2), 66
(ii.3), 64 (ii.7), 63 (ii.10), 67 (ii.4) and 65 (ii.5). None had
ophthalmological problems. No genetic material was
available for molecular confirmation of diagnosis.
Family 7
The proband (ii.3) was a 31-year old female who pre-
sented with an 8-year history of progressive unsteadiness
and slurred speech. The general physical examination
was normal. Her neurological examination found mild
cerebellar gait and limb ataxia, dysarthria, and slow eye
movements, along with decreased vibration sense and
reflexes. She had mild memory loss, and fundoscopy was
unremarkable. MRI of the brain showed mild cerebellar
atrophy. The patient refused permission to collect blood
for DNA analysis. The proband’s mother was Zambian.
Her father (i.2) was Sierra-Leonean, and developed
balance issues in his mid-50s. Another daughter (ii.6),
born from a Sierra Leonean marriage, developed un-
steady gait in her early 30s and slurred speech by the
age 36. No genetic material was available for molecular
confirmation of diagnosis.
Discussion and conclusions
Five affected families were ethnic Zambians from various
tribes (including Bemba, Nyanja, Lozi, and Kunda), ori-
ginating from different regions of the country (Eastern,
Western and Central province). The Kunda tribe are
found in Eastern Province of Zambia. And interestingly,
this tribe is also found in Zimbabwe and Mozambique.
Two families were of mixed ancestry (one Zambian
and Zimbabwean, one Zambian and Sierra-Leonean). In
all families, the disease had an autosomal dominant pat-
tern of inheritance across multiple generations.
The ADCAs are rare disorders with an estimated glo-
bal prevalence of 2-7 per 100 000 [2]. The frequency of
these disorders varies widely in different populations and
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geographical regions. Studies conducted worldwide show
that in many countries SCA3 is the most common
ataxia, followed by SCA2 and SCA6. A relatively high
frequency of SCA3 has been seen in Brazil [18], Portugal
[19], China [20], Japan [21], Thailand [22], the
Netherlands, and Germany [3]; but is lower in France,
Canada, and USA; and rare in Italy, Norway and India
[3]. A high prevalence of SCA2 was found in Cuba [23]
and Mexico [24, 25]. Four of the seven Zambian families
studied showed phenotypes typical of SCA7, including
the characteristic presence of retinopathy. SCA7 is
caused by the expansion of a CAG repeat tract in the
ataxin-7 gene (ATXN7), which translates into a
polyglutamine-expanded protein. The mutated protein,
causes neuronal loss in the cerebellum, brainstem and
retina [26, 27]. Pathogenic, expanded alleles typically
contain between 38 and 70 repeats, but extreme expan-
sions – up to 460 CAG – have been documented [28].
SCA7 is a relatively rare form of ADCA, but has variable
frequencies in different regions [10, 11, 25, 29, 30]. The
risk of CAG triplet expansion into the disease-associated
range is frequently associated with haplotypes, making indi-
viduals with certain haplotypes at lower or higher risk for
the disease [31]. The relative frequency of SCA7 is consid-
erably higher in certain regions of the world, including
Mexico, South Africa and Scandinavia, and is associated
with local founder effects in those areas [12, 24, 30, 32].
Reports on SCA7 in the African continent are scarce,
although there are isolated reports from Algeria, Angola,
Cape Verde, Liberia, Mali, Morocco, South Africa and
Tunisia [9, 13, 18, 26, 33, 34]. SA has one of the highest
frequencies of SCA7 in the world. Moreover, the SCA7
mutations in SA have only been found in families of
Black ethnic origin [10–13]. A haplotype study in 13
families from the indigenous Black African population of
SA provided evidence for a SCA7 founder effect [11,
12]. Importantly, haplotype studies based on Families 1
and 4 have confirmed that this SA SCA7 haplotype ex-
tends to northern Namibia and Zambia [35]. Consider-
ing the geographical distribution of these families, it’s
feasible to hypothesize that the South African SCA7
founder effect extends to additional neighbouring coun-
tries such as Botswana and Zimbabwe. Population-based
haplotype studies may give important insights into the
origins of pathogenic mutations, and can assist in the
design of therapeutic interventions, such as RNA inter-
ference or CRISPR based modalities.
The main phenotypes in families 1, 2, 3 and 4 were
gait and limb ataxia, dysarthria, visual loss, ptosis,
ophthalmoparesis or ophthalmoplegia, pyramidal tract
signs and dementia. The combination of these symptoms
with retinal degeneration and cerebellar atrophy are in
line with SCA7, which was molecularly confirmed fam-
ilies 1, 2 and 4. All families displayed anticipation of
both onset age and rate of disease progression. There
was marked anticipation in age of onset in Family 1
(Table 1). Moreover, the rate of the disease progression
was significant in the proband and his mother, with the
mother of the proband dying 7 years after disease onset
and the proband dying 9 years after disease onset. The
proband, his mother, grandfather and aunt also displayed
symptoms of spasticity. SCA7 and hereditary spasticity
may co-exist within this family.
In the proband and his affected brother in family 2,
cerebellar ataxia correlated with cerebellar atrophy,
decreased visual acuity with macular degeneration and
cortical degeneration with cognitive impairment. This sug-
gests that motor systems could degenerate in parallel with
visual systems and cognitive decline with cortical degener-
ation, although it is difficult to determine whether the de-
generation in motor, visual and cortical systems is caused
by the same mechanisms.
In general, SCA7 anticipation is commonly observed
through paternal transmission. Analysis of the dynamic
mutation in the SCA7 gene may show marked parental ef-
fects on CAG repeat transmission. In families 1, 2 and 3,
the third generation had maternal transmission, which,
may be an important factor for anticipation of age of onset
and the rate of disease progression. Genetic anticipation
through the maternal transmission has previously been re-
ported in Japanese families [36]. In family 4, the disease
had paternal transmission and the affected grandfather of
the proband was Zimbabwean. The clinical characteristics
of Zambian families with SCA7 are similar to families de-
scribed in Africa and other countries. The presence of
progressive cerebellar ataxia, macular degeneration or
optic atrophy, slow eye movements or ophthalmoparesis
and pyramidal symptoms associated with cerebellar atro-
phy in brain imaging suggests that clinical picture of
SCA7 is relatively homogenous.
The combination of cerebellar symptoms with slow
saccadic eye movements, peripheral neuropathy, dementia
and tremor suggest phenotypic presentation of ADCA in
families 5, 6 and 7. All three families displayed marked
anticipation of onset age. These features suggest that these
families are likely to be affected with a different type of
SCA possibly caused by a polyglutamine repeat expansion
(SCA1, 2, 3, 6, 12 and 17), but genetic material was not
available for molecular analysis. Family 7 was of mixed
ancestry. The affected Sierra-Leonean father of the
proband had affected daughters from Sierra-Leonean and
Zambian marriages, suggesting that the origin of the
mutation in this family may be Sierra Leonean.
In conclusion, we have shown that SCA is evident in
ethnic Zambian families. These findings imply that all
ethnic Zambian patients with suspected inherited ataxia
should have molecular genetic testing. Furthermore,
these families should be counselled with their relatives
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who are at risk of inheriting the altered gene. Further
clinical and genetic studies of the prevalence of the
spinocerebellar ataxias in a larger cohort of patients may
help shed light on the natural history and origin of these
disorders in the Zambian population.
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